South Korea
SK pharmteco doubles viral vector production capacity in Europe
SEOUL, South Korea, June 22, 2023 /PRNewswire/ -- SK pharmteco, SK Inc.'s contract development manufacturing organization (CDMO) for pharmaceuticals, successfully completed its second facility for Cell and Gene Therapies (C>) manufacturing in Europe.
SK bioscience COVID-19 Vaccine Granted Emergency Use Listing by the World Health Organization
SEONGNAM, South Korea, June 19, 2023 /PRNewswire/ -- SK bioscience, a global innovative vaccine and biotech company committed to promoting human health from prevention to cure, announced the company has received the WHO Emergency Use Listing (EUL) of its COVID-19 vaccine, SKYCovione.
GC Genome’s New Study Reveals Link Between Gut Microbiome and High Blood Pressure
YONGIN, South Korea, June 14, 2023 /PRNewswire/ -- GC Genome Corporation, a leading genomic diagnostics company, announced the publication of a study in Frontiers in Microbiomes.
Gencurix Obtains Approval for Companion Diagnostic of Digital PCR-based EGFR Mutation Test
SEOUL, South Korea, June 13, 2023 /PRNewswire/ -- Gencurix, a leading cancer molecular diagnostics company, has obtained approval from the Korean Ministry of Food and Drug Safety for its Droplex EGFR Mutation Test v2.
Springer Nature to Join Seegene’s OneSystem™ Business as Strategic Partner
SEOUL, South Korea, June 15, 2023 /PRNewswire/ -- Seegene Inc. (KQ096530), a leading South Korean company providing a total solution for PCR molecular diagnostics, announced today that it has signed a strategic partnership agreement with Springer Nature to expand its OneSystem™ Business.
OliX Pharmaceuticals Administers First Patient in Phase 1 Clinical Study of RNAi Therapeutic OLX72021 for Androgenic Alopecia
SUWON, South Korea--(BUSINESS WIRE)--OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, announced today that the first patient has been administered on June 5, in a Phase 1 clinical trial, evaluating OLX72021, an investigational RNAi therapeutic intended for the treatment of androgenic alopecia, also known as male-pattern baldness.
MindRank Announces First-in-Human Phase 1 Study of MDR-001 in China
SHANGHAI and HANGZHOU, China, June 14, 2023 /PRNewswire/ -- MindRank, a clinical stage artificial intelligence (AI)-empowered drug discovery company, announced today that the first healthy volunteer dosed in the Phase 1 study of their oral small-molecule glucagon-like peptide 1 receptor agonist (GLP-1 RA), MDR-001 for the treatment of obesity and type 2 diabetes mellitus (T2DM).
Seegene and Werfen Partner to Collaborate on OneSystem™ Business to Develop Syndromic qPCR Assays
SEOUL, South Korea, June 14, 2023 /PRNewswire/ -- Seegene Inc. (KQ096530), a leading South Korean company which provides a total solution for PCR molecular diagnostics, announced an agreement with Werfen, a worldwide leader in Specialized Diagnostics, to advance discussions on the expansion of its current collaboration for the Spanish and Portuguese marketplaces through Seegene's OneSystem™ Business.
HanAll Biopharma and Daewoong Pharmaceutical Co-invest in Vincere Biosciences for Collaborative Opportunities in Parkinson’s Disease
ROCKVILLE, Md. and SEOUL, South Korea, June 12, 2023 /PRNewswire/ -- HanAll Biopharma (KRX: 009420.KS) and Daewoong Pharmaceutical (KRX: 069620.KS) today announced the expansion of their open collaboration strategy by investing in Vincere Biosciences, a Cambridge, MA-based company developing therapeutics targeting mitophagy.
Samsung Biologics and Pfizer announce strategic collaboration for long-term manufacturing of biosimilars portfolio
Samsung Biologics (KRX:207940.KS) and Pfizer (NYSE: PFE) today announced a strategic partnership for the long-term commercial manufacturing of Pfizer’s multi-product portfolio.
